#### Check for updates

#### OPEN ACCESS

EDITED BY Sergio Conti, ARNAS Ospedali Civico Di Cristina Benfratelli, Italy

REVIEWED BY Maurizio Del Greco, Hospital Santa Maria del Carmine, Italy Giuseppe Mascia, University of Genoa, Italy

\*CORRESPONDENCE Rui Wang ⊠ wangrui\_sxmu@163.com

SPECIALTY SECTION This article was submitted to Cardiac Rhythmology, a section of the journal Frontiers in Cardiovascular Medicine

RECEIVED 03 October 2022 ACCEPTED 14 December 2022 PUBLISHED 06 January 2023

#### CITATION

Pang N, Gao J, Zhang N, Guo M and Wang R (2023) Cavotricuspid isthmus ablation for atrial flutter guided by contact force related parameters: A systematic review and meta-analysis. *Front. Cardiovasc. Med.* 9:1060542. doi: 10.3389/fcvm.2022.1060542

#### COPYRIGHT

© 2023 Pang, Gao, Zhang, Guo and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License

(CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

## Cavotricuspid isthmus ablation for atrial flutter guided by contact force related parameters: A systematic review and meta-analysis

Naidong Pang <sup>(b)</sup> <sup>1,2</sup>, Jia Gao<sup>1</sup>, Nan Zhang<sup>1</sup>, Min Guo<sup>1</sup> and Rui Wang<sup>1\*</sup>

<sup>1</sup>Department of Cardiology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China, <sup>2</sup>The First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China

**Background:** Contact force (CF) and related parameters have been evaluated as an effective guide mark for pulmonary vein isolation, yet not for linear ablation of the cavotricuspid isthmus (CTI) dependent atrial flutter (AFL). We thus studied the efficacy and safety of CF related parameter-guided ablation for CTI-AFL.

**Methods:** Systematic search was performed on databases involving PubMed, EMbase, Cochrane Library and Web of Science (through June 2022). Original articles comparing CF related parameter-guided ablation and conventional parameter-guided ablation for CTI-AFL were included. Oneby-one elimination, subgroup analysis and meta-regression were used for heterogeneity test between studies.

**Results:** Ten studies reporting on 761 patients were identified after screening with inclusion and exclusion criteria. Radiofrequency (RF) duration was significantly shorter in CF related parameter-guided group (p = 0.01), while procedural time (p = 0.13) and fluoroscopy time (p = 0.07) were no significant difference between two groups. CF related parameter-guided group had less RF lesions (p = 0.0003) and greater CF of catheter-tissue (p = 0.0002). Touch-up needed after first ablation line was less in CF related parameter-guided group (p = 0.004). In addition, there were no statistical significance between two groups on acute conduction recovery rates (p = 0.25), recurrence rates (p = 0.92), and complication rates (p = 0.80). Meta-regression analysis

revealed no specific covariate as an influencing factor for above results (p > 0.10).

**Conclusion:** CF related parameters guidance improves the efficiency of CTI ablation, with the better catheter-tissue contact, the lower RF duration and the comparable safety as compared with conventional method, but does not improve the acute success rate and long-term outcome.

KEYWORDS

atrial flutter, cavotricuspid isthmus, catheter ablation, contact force, ablation index

## 1. Introduction

Cavotricuspid isthmus (CTI) dependent atrial flutter (AFL), also known as typical AFL, is the most common macroreentrant atrial tachycardia which can lead to thromboembolic events and heart failure (1). As the critical zone of slow conduction, CTI is the ideal target to interrupt the reentrant circuit (2, 3). Currently, radiofrequency (RF) catheter ablation (CA) has become an effective treatment for CTI-AFL (4, 5), whereas there is still a recurrence rate of more than 5% which often related to re-connection of isthmus (6).

Previous studies have shown the importance of transmural lesion for effective and long-lasting RF lesion (7). Sufficient contact between the ablation catheter tip and the target tissue is crucial to achieve transmural necrosis and scar formation (8), whereas excessive tissue contact may be potentially hazardous (9). Therefore, optimal tissue contact has become one of the pursuits of electrophysiologists for RF ablation. Although traditional CTI ablation can indirectly observe catheter-tissues contact using a combination of qualitative measures, such as reduced catheter movements and electrogram amplitudes, these methods are not accurate enough. With the development of ablation-assisted techniques, more parameters have been available for quantitative assessment of catheter-target tissue contact. Contact force (CF) as a new parameter reflecting the real-time catheter tip-tissue contact, had been confirmed to help transmural lesion formation in pulmonary vein isolation (PVI) (10). Previous studies have suggested that use of optimal CF value during PVI is associated with increased lesion volumes, and provides greater security in complication risks such as cardiac perforation (11, 12). In addition, in recent years, there are some CF related parameters, which have similar principle and function with CF, and also reflect the catheter-tissue contact, have been utilized in AFL ablation. Ablation index (AI) is an updated parameter of atrial fibrillation (AF) ablation, which incorporates CF, time, and power though a special algorithm, and can be reflected in real time during the ablation (13). Electrical coupling index (ECI) is another catheter-tissue contact related parameter created for AF ablation. ECI does not give direct information about the pressure of catheter tip-tissue interface, but reflects the real-time complex impedance and describes characteristic of tissue heating and lesion formation.

The effect of these parameters in achieving transmural lesion has been demonstrated in AF ablation (14–16), but there is a lack of evidence that they are equally effective in CTI-AFL ablation. Recently, there have been some relevant studies on influences of CF related parameters in CTI-AFL ablation, but results of these small, single center studies were not completely same. Accordingly, we conducted a meta-analysis to assess feasibility, safety and efficacy of CTI-AFL ablation guided by CF related parameters.

## 2. Methods

### 2.1. Data sources and search strategies

This meta-analysis was performed referring to established methods (17). An electronic databases search was performed on PubMed, EMbase, Cochrane Library and Web of Science (from inception to July 2022) by two independent reviewers (N.P., J.G.), using the following search terms: "atrial flutter," "cavotricuspid isthmus," "catheter ablation," "radiofrequency ablation," "contact force," "ablation index" and "electrical coupling index" with no language restriction. Additional literature was further searched from review articles and references of relevant researches manually. Any discrepancies were arbitrated by the third reviewer (R.W.).

# 2.2. Study selection and quality assessment

Inclusion criteria were applied as follows: (a) randomizedcontrolled trials (RCTs) and observational studies on RF ablation of CTI-AFL; (b) compared to procedural parameters and clinical outcomes between CF related parameters-guided and conventional parameters-guided ablation; (c) baseline information and outcome data were complete and accurate. Reviews, case reports, editorials, single cohort studies, and animal studies were excluded. Included studies were not restricted by race, sex, age, or research country.

Two independent reviewers (N.P., J.G.) formally performed quality assessment. RCTs were evaluated using the Cochrane Collaboration bias risk assessment tool (18). Non-RCTs were assessed using the Newcastle-Ottawa Scale (NOS), with scores varying from 0 to 9 depending on the quality of studies, and papers were considered high quality if they scored 7 or higher. Any disagreements were adjudicated by the third reviewer (R.W.).

### 2.3. Data extraction

Two reviewers (NP and JG) independently extracted the data from the original articles and raw data files of all eligible studies, and entered into a predetermined spreadsheet as follows: (a) study information (first author's name, published year, research country, type of study design, sample size, parameters that guide ablation); (b) participant characteristics (mean age, male gender, race, and baseline characteristics); (c) outcome indicators: RF duration, total procedural time, fluoroscopy time, RF lesion numbers, average CF values,

acute conduction recovery, touch-up needed, recurrence/reconduction rates, and risk of complications.

### 2.4. Statistical analysis

Statistical analyses in this meta-analysis were performed with Review Manager (RevMan, version 5.3) and Stata (version 12.0). The mean difference or standard mean difference and respective 95% confidence intervals (95% CI) were used as the measure of data for continuous variables, risk ratio (RR) and respective 95% CI were used as the measure of data for binary variables. If the heterogeneity across studies was less than 50%, data were pooled using fixed-effect model, otherwise, the random-effect model was used. Statistical significance was set as *p*-value of less than 0.05. Data of continuous variables represented by median and interquartile range were converted to mean and standard deviation to perform data synthesis and statistical analyses after checking for the normal distribution (19, 20). Heterogeneity was assessed by calculating  $I^2$  and Cochran Q test, with  $I^2$  value more than 50% or p-value of the Q test less than 0.1 was considered evidence of significant inconsistency (21, 22). If heterogeneity was present, sensitivity analysis was conducted to inspect the effect of a single study on



the overall risk estimate by omitting one study at a time. Metaregression analysis was also performed to examine the sources of differences among studies. If a particular covariate had a significant effect on heterogeneity (p < 0.10), further subgroup analysis was performed. We generated funnel plot to assess potential publication bias, and the asymmetry of the plot was evaluated by Egger's test, with *p*-value of less than 0.05 indicating apparent asymmetry.

## 3. Results

### 3.1. Search results

The thorough literature search resulted in 144 records (141 from electronic databases and three from manual search). 36 duplicate studies were removed from the search results. After screening based on the inclusion and exclusion criteria, 21 studies were selected for full-text review. Of these, 11 studies were further excluded because no clear outcome data or no control group were available. Ten studies were eventually identified and included in the meta-analysis, which involved four RCTs (23–25) and six observational studies (26–31). Figure 1 shows the flowchart of the inclusions and exclusions.

## 3.2. Study characteristics and quality assessment

Included studies were conducted in centers across the United Kingdom, Canada, Denmark, Australia, and Japan. A total of 761 patients were enrolled in the entire cohort, 437 (57.4%) underwent ablation guided by CF related parameters and 324 (42.6%) underwent conventional parameters-guided ablation (control group). The mean age of the participants

was 66.1 years, and there were predominantly males (78.2%). Regarding the ablation parameters, seven studies performed procedures guided by CF parameter, two guided by ECI, and one guided by AI. The summary of study characteristics is presented in Table 1. All included studies performed procedures using point-by-point ablation from the tricuspid valve annulus to the inferior cava veins, and clearly verified the bidirectional block after ablation and at procedure end by a separate double potential at the distal bipoles of an ablation catheter during the CS pacing and differential pacing maneuvers.

The four RCTs were assessed as high quality according to the Cochrane Collaboration criteria, although partial possible biases were unclear. The six observational studies were classified as high quality based on at least seven point of NOS scores, indicating a low risk of bias and suitable for analysis. Figure 2 and Table 2 show the results of quality assessment for RCTs and observational studies, respectively.

# 3.3. Outcomes of procedural parameters

The differences of RF duration, procedural time, fluoroscopy time, average CF values, and number of RF lesions were assessed between the two groups.

RF duration was available in eight studies. Of these, five studies favored the guided by CF related parameters, whereas three studies had the opposite results. Pooled analysis showed that CF related parameters-guided ablation had a statistically significant shorter RF duration (SMD: -0.37, random-effect model, -0.65 to -0.09, p = 0.01; Figure 3A) with moderate heterogeneity across studies ( $I^2 = 52\%$ , p = 0.04 of Q-test).

In addition, there were seven studies and eight studies, respectively, reported the procedural time and fluoroscopy time. The results of quantitative synthesis showed that CF

TABLE 1	Summary	of included	studies.
---------	---------	-------------	----------

References	Research country	Study design	Parameter	Sample size	Age mean (± <i>SD</i> )	Males <i>n</i> (%)
Begg et al. (23)	UK	RCT	CF	53	64.0 (11.5)	45 (84.9)
Begg et al. (23)	UK	RCT	ECI	45	63.7 (10.9)	39 (86.7)
Boles et al. (26)	Canada	Retrospective study	CF	38	67.4 (9.5)	26 (68.4)
Giehm-Reese et al. (24)	Denmark	RCT	CF	156	67.6 (9.7)	120 (76.9)
Gould et al. (27)	Australia	Retrospective study	CF	60	64.0 (9.5)	47 (78.3)
Gül et al. (28)	Canada	Retrospective study	CF	37	66.2 (10.0)	26 (70.3)
Jones et al. (25)	UK	RCT	ECI	101	65.5 (11.0)	79 (78.2)
Sakama et al. (29)	Japan	Prospective study	AI	181	68.2 (9.7)	133 (73.5)
Saraf et al. (30)	UK	Retrospective study	CF	20	65.5 (8.5)	19 (95.0)
Venier et al. (31)	Canada	Retrospective study	CF	70	62.7 (10.9)	61 (87.1)

UK, United Kingdom; RCT, randomized controlled trial; CF, contact force; ECI, electrical coupling index; AI, ablation index.



TABLE 2 Quality	assessment	of	non-RCTs.
-----------------	------------	----	-----------

References	Study design	NOS score
Boles et al. (26)	Retrospective study	8
Gould et al. (27)	Retrospective study	7
Gül et al. (28)	Retrospective study	7
Sakama et al. (29)	Prospective study	7
Saraf et al. (30)	Retrospective study	9
Venier et al. (31)	Retrospective study	8

RCT, randomized controlled trials; NOS, Newcastle-Ottawa Scale.

related parameters-guided ablation was associated with shorter procedural time (SMD: -0.25, random-effect model, -0.56 to 0.07, p = 0.13; moderate heterogeneity,  $I^2 = 65\%$ ) (Figure 3B) and fluoroscopy time (SMD: -0.42, random-effect model, -0.87 to 0.03, p = 0.07; high heterogeneity,  $I^2 = 86\%$ ) (Figure 3C) compared to conventional parameters-guided ablation, but did not reach statistical significance.

Regarding the number of RF lesions to achieve CTI bidirectional block, analysis of available data from six studies showed that ablation guided by CF related parameters was associated with less RF lesions compared to that guided by

conventional parameters (SMD: -0.35, fixed-effect model, -0.54 to -0.16, p = 0.0003; low heterogeneity,  $I^2 = 39\%$ ) (Figure 3D).

Average CF values during ablation were reported in five of the seven studies on CF parameter, with data from three studies of which were available for comparison. The average CF values of CF-guided group was 15.1 grams (g) (from five studies), while that was 13.2 g of control group. Pooled analysis showed that CF-guided ablation was characterize by significantly increased catheter-tissue contact (MD: 2.68, fixed-effect model, 1.26–4.11, p = 0.0002; Figure 3E) with low heterogeneity ( $I^2 = 43\%$ , p = 0.18).

### 3.4. Ablation efficacy and safety

Ablation guided by CF related parameters was associated with a higher success rate of bidirectional isthmus block after first ablation line achieved according our analysis, which meant less cases needed touch-up (16.6% vs. 24.9%, RR: 0.57, fixed-effect model, 0.39–0.84, p = 0.004; Figure 4A). An extremely low heterogeneity was observed ( $I^2 = 0\%$ , p = 0.91).

A total seven studies reported the information of acute conduction recovery after procedures (approximately 20–30 min after achieving CTI bidirectional block). There was no significant difference between the two groups (7.6% vs. 10.6%, RR: 0.74, fixed-effect model, 0.44–1.24, p = 0.25; **Figure 4B**) with an extremely low heterogeneity across studies ( $I^2 = 0\%$ , p = 0.48).

In terms of recurrence rates, ablation guided by CF related parameters showed similar risk as the control group (15.4% vs. 15.5%, RR: 1.02, fixed-effect model, 0.66–1.58, p = 0.92; **Figure 4C**).  $I^2$  was 0%, which indicated an extremely low heterogeneity.

The ablation complication risks of the two groups were no statistically significant which the data were obtained from five studies (RR: 0.94, fixed-effect model, 95% CI, 0.59–1.51, p = 0.80; **Figure 4D**). An extremely low heterogeneity was found ( $I^2 = 0\%$ , p = 0.65).

# 3.5. Publication bias assessment for included studies

No significant publication biases were found in all nine observed indicators of included studies by funnel plots and Egger's tests (**Figure 5**).

# 3.6. Sensitivity analysis and subgroup analysis

Sensitivity analysis was performed to examine the solidity of the results of this work and the sources of heterogeneity between studies. The results of omitting one study at a time showed no

Study or Subgroup	CF Mean	related	Total	C Mean	Control	Total	: Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
Begg CF 2019		636.09	26		407.78	27	13.1%	-0.20 [-0.74, 0.34]	
Begg ECI 2019			22		564.18	23	11.2%	-1.03 [-1.65, -0.40]	-
Boles 2017	306	138	15	456	288	23	10.4%	-0.61 [-1.28, 0.06]	
Gould 2016	787.2	134.4	30	921.2	175.47	30	13.3%	-0.85 [-1.38, -0.32]	
Gül 2018	677.27	846.62	19	636.21	372.46	18	10.8%	0.06 [-0.58, 0.71]	
Jones 2014	580	312	50	574	287	51	17.0%	0.02 [-0.37, 0.41]	<b>_</b>
Sakama 2022	252			306					
		144	151		150	30	16.9%	-0.37 [-0.76, 0.02]	
Saraf 2022	342	120	10	336	162	10	7.3%	0.04 [-0.84, 0.92]	
									•
Total (95% CI)	0.00.01.12	- 44 57	323	(D - 0 0	1) 12 - 50		100.0%	-0.37 [-0.65, -0.09]	
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:		,		(P = 0.0	4); 1- = 52	70			-2 -1 0 1 2 Favours CF related Favours Control
Study or Subgroup		related	Total M		ontrol SD To	ntal M		td. Mean Difference IV. Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
Begg CF 2019		26.12	26		26.22		13.8%	-0.26 [-0.80, 0.28]	
Begg ECI 2019	74	15.06	22	97	18.17	23 1	11.6%	-1.35 [-2.00, -0.70]	
Boles 2017	87.7	24.2	15	93.2	46.3	23 1	11.7%	-0.14 [-0.79, 0.51]	
Giehm 2020	49.94			51.41			18.8%	-0.09 [-0.40, 0.23]	-
Gül 2018	82.84			71.47			11.7%	0.34 [-0.31, 0.99]	
Jones 2014	62.7	33	50	62.3	33	51 1	17.1%	0.01 [-0.38, 0.40]	T
Venier 2017	82.6	24.5	35 1	101.3	60	35 1	15.2%	-0.40 [-0.88, 0.07]	
			245			DE4 4	00.00/	0.051050.007	
Total (95% CI) Heterogeneity: Tau <sup>2</sup> =	= 0 11. Ch	i <sup>2</sup> = 17 0/	245 0 df = 6	3 (P = 0		254 10 = 65%	10.0%	-0.25 [-0.56, 0.07]	+ + + + + + + + + + + + + + + + + + + +
Test for overall effect:				5 (1 - 0	.003), 1 -	0070			-4 -2 0 2 4 Favours CF related Favours Control
		related			Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Begg CF 2019	137	148.24	26	238	3 171.41	27	12.2%	-0.62 [-1.17, -0.07]	
Begg ECI 2019	123	3 140.27	22	311	305.8	23	11.7%	-0.77 [-1.38, -0.16]	
Boles 2017	648			738		23	11.4%	-0.13 [-0.79, 0.52]	
Giehm 2020		5 317.23			5 317.31	77	13.9%	-0.06 [-0.37, 0.26]	1
Gül 2018	1,068.08	913.1	19	888.25	5 434.41	18	11.4%	0.24 [-0.40, 0.89]	
Jones 2014	718	3 577	50	721	583	51	13.4%	-0.01 [-0.40, 0.38]	+
Sakama 2022	12	2 24	151	102	2 120	30	13.1%	-1.69 [-2.12, -1.26]	
Venier 2017	492			612		35	12.8%		
			396			284	100.0%	-0.42 [-0.87, 0.03]	•
Total (95% CI)				P < 0.00	0001); I² =		100.070	-0.42 [-0.01, 0.00]	- $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
Total (95% CI) Heterogeneity: Tau <sup>2</sup> =	0.36; Chi <sup>2</sup>	= 49.95,	(						
									Favours CF related Favours Control
Heterogeneity: Tau <sup>2</sup> =	Z = 1.81 (F	P = 0.07)		Cor	itrol		Std	I. Mean Difference	
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2	Z = 1.81 (F CF	P = 0.07) related	otal M		ntrol SD Tota	<u>al W</u> e		I. Mean Difference IV, Fixed, 95% Cl	Std. Mean Difference IV. Fixed, 95% Cl
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: Study or Subgroup	Z = 1.81 (F CF <u>Mean</u>	P = 0.07) related SD T	otal M	lean	SD Tot		ight	IV, Fixed, 95% CI	Std. Mean Difference
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Study or Subgroup Boles 2017	Z = 1.81 (F CF <u>Mean</u> 8.3	P = 0.07) related <u>SD T</u> 7.6	<u>otal M</u> 15	<u>lean</u> 13.2	<u>SD Tot</u> 9 2	23 8	eight 3.1%	IV. Fixed, 95% CI -0.57 [-1.23, 0.10]	Std. Mean Difference
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 3 Study or Subgroup Boles 2017 Giehm 2020	Z = 1.81 (F CF <u>Mean</u>	P = 0.07) related <u>SD T</u> 7.6 6.04	<u>otal M</u> 15	<u>lean</u> 13.2 5.41 6	<u>SD Tot</u> 9 2 5.04 7	23 8 77 35	aight 3.1% 5.3%	IV, Fixed, 95% CI -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08]	Std. Mean Difference
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 3 Study or Subgroup Boles 2017 Giehm 2020	Z = 1.81 (F CF <u>Mean</u> 8.3	P = 0.07) related <u>SD T</u> 7.6	<u>otal M</u> 15	<u>lean</u> 13.2	<u>SD Tot</u> 9 2 6.04 7	23 8 77 35	eight 3.1%	IV. Fixed, 95% CI -0.57 [-1.23, 0.10]	Std. Mean Difference
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Study or Subgroup Boles 2017 Giehm 2020 Gould 2016	Z = 1.81 (F CF <u>Mean</u> 8.3 13 19	P = 0.07) related <u>SD T</u> 7.6 6.04 14	<u>otal M</u> 15 78 1 30	13.2 5.41 6 22	<u>SD Tot</u> 9 2 5.04 7 13 3	23 8 77 35 30 13	e <b>ight</b> 3.1% 5.3% 3.9%	IV. Fixed, 95% Cl -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08] -0.22 [-0.73, 0.29]	Std. Mean Difference
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Study or Subgroup Boles 2017 Giehm 2020 Gould 2016 Sakama 2022	Z = 1.81 (F CF <u>Mean</u> 8.3 13 19 11	P = 0.07) related <u>SD T</u> 7.6 6.04 14 5	Total M 15 78 1 30 151	13.2 5.41 6 22 12	SD         Tota           9         2           5.04         7           13         3           4         3	23 8 77 35 80 13 80 23	ight 3.1% 5.3% 3.9% 3.2%	IV. Fixed. 95% Cl -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08] -0.22 [-0.73, 0.29] -0.21 [-0.60, 0.19]	Std. Mean Difference
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Study or Subgroup Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022	Z = 1.81 (F CF <u>Mean</u> 8.3 13 19 11 12.6	P = 0.07) related SD T 7.6 6.04 14 5 6.5	Total M 15 78 1 30 151 10	13.2 13.2 5.41 6 22 12 9.2	SD         Tota           9         2           5.04         7           13         3           4         3           3.5         1	23 8 77 35 30 13 30 23 10 4	ight 3.1% 5.3% 3.9% 3.2% 4.4%	IV. Fixed, 95% Cl -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08] -0.22 [-0.73, 0.29] -0.21 [-0.60, 0.19] 0.62 [-0.28, 1.53]	Std. Mean Difference
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022 Venier 2017	Z = 1.81 (F CF <u>Mean</u> 8.3 13 19 11	related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34	Total         M           15         78         1           30         151         10           35         2	13.2 5.41 6 22 12	SD         Tots           9         2           5.04         7           13         3           4         3           3.5         1           18.4         3	23 8 77 35 30 13 30 23 10 4 35 15	3.1% 5.3% 3.9% 3.2% 1.4% 5.2%	IV. Fixed, 95% Cl -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08] -0.22 [-0.73, 0.29] -0.21 [-0.60, 0.19] 0.62 [-0.28, 1.53] -0.74 [-1.22, -0.25]	Std. Mean Difference
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022 Venier 2017	Z = 1.81 (F CF <u>Mean</u> 8.3 13 19 11 12.6	related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34	Total M 15 78 1 30 151 10	13.2 13.2 5.41 6 22 12 9.2	SD         Tots           9         2           5.04         7           13         3           4         3           3.5         1           18.4         3	23 8 77 35 30 13 30 23 10 4	3.1% 5.3% 3.9% 3.2% 1.4% 5.2%	IV. Fixed, 95% Cl -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08] -0.22 [-0.73, 0.29] -0.21 [-0.60, 0.19] 0.62 [-0.28, 1.53]	Std. Mean Difference
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022 Venier 2017 Total (95% CI)	Z = 1.81 (F CF <u>Mean</u> 8.3 13 19 11 12.6 12.47	P = 0.07) related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34	Total         M           15         78         1           30         151         10           35         2         319	Iean           13.2           5.41         6           22           12           9.2           2.92         1	SD         Tot:           9         2           5.04         7           13         3           4         3           3.5         1           18.4         3	23 8 77 35 30 13 30 23 10 4 35 15	3.1% 5.3% 3.9% 3.2% 1.4% 5.2%	IV. Fixed, 95% Cl -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08] -0.22 [-0.73, 0.29] -0.21 [-0.60, 0.19] 0.62 [-0.28, 1.53] -0.74 [-1.22, -0.25]	Std. Mean Difference IV. Fixed, 95% Cl
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022 Venier 2017 Total (95% CI) Heterogeneity: Chi <sup>2</sup> =	Z = 1.81 (F CF <u>Mean</u> 8.3 13 19 11 12.6 12.47 = 8.19, df =	related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34 = 5 (P = 1	Total M 15 78 1 30 151 10 35 2 319 0.15); I <sup>2</sup>	Iean           13.2           5.41         6           22           12           9.2           2.92         1	SD         Tot:           9         2           5.04         7           13         3           4         3           3.5         1           18.4         3	23 8 77 35 30 13 30 23 10 4 35 15	3.1% 5.3% 3.9% 3.2% 1.4% 5.2%	IV. Fixed, 95% Cl -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08] -0.22 [-0.73, 0.29] -0.21 [-0.60, 0.19] 0.62 [-0.28, 1.53] -0.74 [-1.22, -0.25]	Std. Mean Difference IV. Fixed, 95% Cl
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Study or Subgroup Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022 Venier 2017 Total (95% CI) Heterogeneity: Chi <sup>2</sup> =	Z = 1.81 (F CF <u>Mean</u> 8.3 13 19 11 12.6 12.47 = 8.19, df =	related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34 = 5 (P = 1	Total M 15 78 1 30 151 10 35 2 319 0.15); I <sup>2</sup>	Iean           13.2           5.41         6           22           12           9.2           2.92         1	SD         Tot:           9         2           5.04         7           13         3           4         3           3.5         1           18.4         3	23 8 77 35 30 13 30 23 10 4 35 15	3.1% 5.3% 3.9% 3.2% 1.4% 5.2%	IV. Fixed, 95% Cl -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08] -0.22 [-0.73, 0.29] -0.21 [-0.60, 0.19] 0.62 [-0.28, 1.53] -0.74 [-1.22, -0.25]	Std. Mean Difference IV. Fixed, 95% Cl
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022 Venier 2017 Total (95% CI) Heterogeneity: Chi <sup>2</sup> =	Z = 1.81 (F CF <u>Mean</u> 8.3 13 19 11 12.6 12.47 = 8.19, df = t: Z = 3.61	related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34 = 5 (P = 1	Total M 15 78 1 30 151 10 35 2 319 0.15); I <sup>5</sup> 0003)	Iean           13.2           5.41         6           22           12           9.2           2.92         1	SD         Tot:           9         2           5.04         7           13         3           4         3           3.5         1           18.4         3	23 8 77 35 30 13 30 23 10 4 35 15 95 100	3.1% 5.3% 3.9% 3.2% 1.4% 5.2%	IV. Fixed, 95% Cl -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08] -0.22 [-0.73, 0.29] -0.21 [-0.60, 0.19] 0.62 [-0.28, 1.53] -0.74 [-1.22, -0.25] -0.35 [-0.54, -0.16] Mean Difference	Std. Mean Difference IV. Fixed, 95% Cl 
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Study or Subgroup Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022 Venier 2017 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect	Z = 1.81 (F CF <u>Mean</u> 8.3 13 19 11 12.6 12.47 = 8.19, df = t: Z = 3.61	P = 0.07) related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34 = 5 (P = 0.0 F related	Total         M           15         78         1           30         151         10           151         35         2           319         0.15); I <sup>2</sup> 1503)	Iean         13.2         5.41       6         22       12         9.2       9.2         '2.92       1         '2.92       1	SD         Tot:           9         2           5.04         7           13         3           4         3           3.5         1           18.4         3           20	23 8 77 35 30 13 30 23 10 4 35 15 95 100	ight 3.1% 5.3% 3.9% 3.2% 4.4% 5.2% 0.0%	IV. Fixed, 95% Cl -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08] -0.22 [-0.73, 0.29] -0.21 [-0.60, 0.19] 0.62 [-0.28, 1.53] -0.74 [-1.22, -0.25] -0.35 [-0.54, -0.16]	Std. Mean Difference IV. Fixed, 95% Cl 
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022 Venier 2017 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect Study or Subgroup	Z = 1.81 (F CF <u>Mean</u> 8.3 13 19 11 12.6 12.47 = 8.19, df = t: Z = 3.61 CF <u>Mean [g</u>	P = 0.07) related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34 = 5 (P = 1 (P = 0.0 F related <u>SD T</u> <u>SD [g]</u>	Total         M           15         78         1           30         151         10           151         35         2           319         0.15); I <sup>2</sup> 1003)	Mean           13.2           5.41           22           12           9.2           22.92           1           2           2           3.2           3.3%	SD         Tot:           9         2           8.04         7           13         3           4         3           3.5         1           8.4         3           20           0           Control           [g]         SD	23 8 77 35 30 13 30 23 10 4 35 15 15 100 1 1 [g] To	ight 3.1% 5.3% 3.9% 3.2% 4.4% 5.2% 0.0%	IV. Fixed, 95% CI -0.57 [-1.23, 0.10] -0.40 [-0.72, -0.08] -0.22 [-0.73, 0.29] -0.21 [-0.60, 0.19] 0.62 [-0.28, 1.53] -0.74 [-1.22, -0.25] -0.35 [-0.54, -0.16] Mean Difference ght IV. Fixed, 95% CI	Std. Mean Difference IV. Fixed, 95% CI
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022 Venier 2017 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect Study or Subgroup Begg CF 2019	Z = 1.81 (F CF <u>Mean</u> 8.3 19 11 12.6 12.47 = 8.19, df = t: Z = 3.61 CF <u>Mean [g</u> 11.3	P = 0.07) related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34 $= 5 (P = 0.0)$ F related <u>1 SD [g]</u> 3 4.35	Total         M           15         78         1           30         151         10           35         2         319           0.15); H         1003)         1	1ean         13.2         5.41         22         12         9.2         22.92         2         2         2         39%	SD         Tot:           9         2           5.04         7           13         3           4         3           3.5         1           8.4         3           20         20           0         20           0         3           0         3           0         3           0         3           0         3           0         3	23 8 77 35 30 13 30 23 10 4 35 15 15 100 1 1 <u>[g] To</u> 82	ight 3.1% 5.3% 3.2% 4.4% 5.2% 0.0% tal Weig 27 26.7	IV. Fixed, 95% Cl           -0.57 [-1.23, 0.10]           -0.40 [-0.72, -0.08]           -0.22 [-0.73, 0.29]           -0.21 [-0.60, 0.19]           0.62 [-0.28, 1.53]           -0.74 [-1.22, -0.25]           -0.35 [-0.54, -0.16]           -           Mean Difference           ght         IV, Fixed, 95% Cl           7%         2.27 [-0.49, 5.03]	Std. Mean Difference IV. Fixed. 95% Cl -2 -2 Favours CF related Favours Control Mean Difference [g] IV. Fixed. 95% Cl [g] 3]
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022 Venier 2017 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect <u>Study or Subgroup</u> Begg CF 2019 Giehm 2020	Z = 1.81 (F CF <u>Mean</u> 8.3 19 11 12.6 12.47 = 8.19, df = t: Z = 3.61 CF <u>Mean [G</u> 11.1 16.7	P = 0.07) related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34 = 5 (P = 0.0 F related <u>SD [g]</u> 3 4.35 1 7.55	Total         M           15         78         1           30         151         10           35         2         319           0.15);         10         10           0.15);         10         10           10         35         2           319         0.15);         10           1003)         1         1           1         1         1           1         1         1           1         1         1           1         1         1           5         26         78	1ean         13.2         5.41         22         12         9.2         :2.92 <td:2.92< td=""> <td:2.92< td=""> <tr< td=""><td>SD         Tot:           9         2           6.04         7           13         3           4         3           3.5         1           8.4         3           20           0         0           0         0           5         3.5           6         1           9         20</td><td>23 8 77 35 30 13 30 23 30 4 35 15 <b>5 100</b> <b>I</b> <b>[g] To</b> 82 09</td><td>ight 3.1% 5.3% 3.9% 3.2% 4.4% 5.2% 0.0% tal Weig 27 26.7 77 20.7</td><td>IV. Fixed, 95% Cl           -0.57 [-1.23, 0.10]           -0.40 [-0.72, -0.08]           -0.22 [-0.73, 0.29]           -0.21 [-0.60, 0.19]           0.62 [-0.28, 1.53]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]</td><td>Std. Mean Difference IV. Fixed, 95% Cl -2 -2 Favours CF related Favours Control Mean Difference [9] IV. Fixed, 95% Cl [9] 3]</td></tr<></td:2.92<></td:2.92<>	SD         Tot:           9         2           6.04         7           13         3           4         3           3.5         1           8.4         3           20           0         0           0         0           5         3.5           6         1           9         20	23 8 77 35 30 13 30 23 30 4 35 15 <b>5 100</b> <b>I</b> <b>[g] To</b> 82 09	ight 3.1% 5.3% 3.9% 3.2% 4.4% 5.2% 0.0% tal Weig 27 26.7 77 20.7	IV. Fixed, 95% Cl           -0.57 [-1.23, 0.10]           -0.40 [-0.72, -0.08]           -0.22 [-0.73, 0.29]           -0.21 [-0.60, 0.19]           0.62 [-0.28, 1.53]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]	Std. Mean Difference IV. Fixed, 95% Cl -2 -2 Favours CF related Favours Control Mean Difference [9] IV. Fixed, 95% Cl [9] 3]
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Venier 2017 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect Study or Subgroup Begg CF 2019 Giehm 2020	Z = 1.81 (F CF <u>Mean</u> 8.3 19 11 12.6 12.47 = 8.19, df = t: Z = 3.61 CF <u>Mean [g</u> 11.3	P = 0.07) related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34 = 5 (P = 0.0 F related <u>SD [g]</u> 3 4.35 1 7.55	Total         M           15         78         1           30         151         10           35         2         319           0.15);         10         10           0.15);         10         10           10         35         2           319         0.15);         10           1003)         1         1           1         1         1           1         1         1           1         1         1           1         1         1           5         26         78	Mean           13.2           5.41           22           12           9.2           22.92           2           2           39%	SD         Tot:           9         2           6.04         7           13         3           4         3           3.5         1           8.4         3           20           0         0           0         0           5         3.5           6         1           9         20	23 8 77 35 30 13 30 23 30 4 35 15 <b>5 100</b> <b>I</b> <b>[g] To</b> 82 09	ight 3.1% 5.3% 3.2% 4.4% 5.2% 0.0% tal Weig 27 26.7	IV. Fixed, 95% Cl           -0.57 [-1.23, 0.10]           -0.40 [-0.72, -0.08]           -0.22 [-0.73, 0.29]           -0.21 [-0.60, 0.19]           0.62 [-0.28, 1.53]           -0.74 [-1.22, -0.25]           -0.35 [-0.54, -0.16]	Std. Mean Difference IV. Fixed, 95% Cl -2 -2 Favours CF related Favours Control Mean Difference [9] IV. Fixed, 95% Cl [9] 3]
Heterogeneity: Tau <sup>2</sup> =	Z = 1.81 (F CF <u>Mean</u> 8.3 19 11 12.6 12.47 = 8.19, df = t: Z = 3.61 CF <u>Mean [G</u> 11.1 16.7	P = 0.07) related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34 = 5 (P = 0.0 F related <u>SD [g]</u> 3 4.35 1 7.55	Total         M           15         78         1           30         151         10           35         2         319           0.15);         10         10           0.15);         10         10           10         35         2           319         0.15);         10           1003)         1         1           1         1         1           1         1         1           1         1         1           1         1         1           5         26         78	Mean         13.2         5.41         22         12         9.2         9.2         22         23         24         12         9.2         22         39%         Mean         5       16         5       5	SD         Tot:           9         2           6.04         7           13         3           4         3           3.5         1           8.4         3           20           0         0           0         0           5         3.5           6         1           9         20	23 8 77 35 30 13 30 23 10 4 35 15 95 100 1 [9] To 82 09 87	ight 3.1% 5.3% 3.9% 3.2% 4.4% 5.2% 0.0% tal Weig 27 26.7 77 20.7	IV. Fixed. 95% Cl           -0.57 [-1.23, 0.10]           -0.40 [-0.72, -0.08]           -0.22 [-0.73, 0.29]           -0.21 [-0.60, 0.19]           0.62 [-0.28, 1.53]           -0.74 [-1.22, -0.25]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]	Std. Mean Difference IV. Fixed, 95% Cl -2 -2 Favours CF related Favours Control Mean Difference [g] IV. Fixed, 95% Cl [g] 3] 4]
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: : Boles 2017 Giehm 2020 Gould 2016 Sakama 2022 Saraf 2022 Venier 2017 Total (95% Cl) Heterogeneity: Chi <sup>2</sup> = Test for overall effect Study or Subgroup Begg CF 2019 Giehm 2020 Venier 2017	Z = 1.81 (F CF <u>Mean</u> 8.3 19 11 12.6 12.47 = 8.19, df = t: Z = 3.61 CF <u>Mean [g</u> 11.3 16.7' 13.1' 3.48, df = 3	$P = 0.07)$ related <u>SD T</u> 7.6 6.04 14 5 6.5 7.34 $= 5 (P = 0.0)$ F related $\frac{SD [g]}{3 + 0.35}$ 1 7.55 1 3.32 2 (P = 0.1)	otal         N           15         78         1           30         151         10         35         2           319         0.15); I'         10 <t< td=""><td>Mean         13.2         5.41         22         12         9.2         9.2         <math>22,2,22,12</math> <math>2^2 = 39\%</math>         1         Mean         5       5         6       5         6       5         7       99.2</td><td>SD         Tot:           9         2           6.04         7           13         3           4         3           3.5         1           8.4         3           20           0         0           0         0           5         3.5           6         1           9         20</td><td>23 8 77 35 30 13 30 23 10 4 35 15 95 100 1 [9] To 82 09 87</td><td>ight 3.1% 5.3% 3.9% 3.2% 4.4% 5.2% 0.0% tal Weig 27 26.1 77 20.1 35 53.2</td><td>IV. Fixed. 95% Cl           -0.57 [-1.23, 0.10]           -0.40 [-0.72, -0.08]           -0.22 [-0.73, 0.29]           -0.21 [-0.60, 0.19]           0.62 [-0.28, 1.53]           -0.74 [-1.22, -0.25]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]</td><td>Std. Mean Difference IV. Fixed, 95% Cl -2 -2 Favours CF related Favours Control Mean Difference [g] IV. Fixed, 95% Cl [g] 3] 4]</td></t<>	Mean         13.2         5.41         22         12         9.2         9.2 $22,2,22,12$ $2^2 = 39\%$ 1         Mean         5       5         6       5         6       5         7       99.2	SD         Tot:           9         2           6.04         7           13         3           4         3           3.5         1           8.4         3           20           0         0           0         0           5         3.5           6         1           9         20	23 8 77 35 30 13 30 23 10 4 35 15 95 100 1 [9] To 82 09 87	ight 3.1% 5.3% 3.9% 3.2% 4.4% 5.2% 0.0% tal Weig 27 26.1 77 20.1 35 53.2	IV. Fixed. 95% Cl           -0.57 [-1.23, 0.10]           -0.40 [-0.72, -0.08]           -0.22 [-0.73, 0.29]           -0.21 [-0.60, 0.19]           0.62 [-0.28, 1.53]           -0.74 [-1.22, -0.25]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]           -0.35 [-0.54, -0.16]	Std. Mean Difference IV. Fixed, 95% Cl -2 -2 Favours CF related Favours Control Mean Difference [g] IV. Fixed, 95% Cl [g] 3] 4]

Forest plots comparing (A) RF duration, (B) total procedural time, (C) fluoroscopy time, (D) number of RF lesions and (E) average CF values between the CF related parameter-guided group and the conventional parameter-guided group.



significant change in research results and heterogeneity, except for one indicator (the same as in the subgroup analysis).

The intervention group of this study included a total three parameters (CF, ECI, and AI), we thus further performed subgroup analysis to separately evaluate the impact of each parameter on CTI ablation. Since the comparison of average CF values only contained CF parameter, so it was not included in the subgroup analysis. The results of the other six outcome indicators showed that only pooled analysis on fluoroscopy time had significant inter-group heterogeneity ( $I^2 = 94.6\%$ ). The source of heterogeneity was the study in AI subgroup, which supported a significant reduction in fluoroscopy time in the intervention group, while the remaining subgroups showed no significant difference (Supplementary Figure 1). Heterogeneity



between subgroups of the other outcome indicators was extremely low ( $I^2 = 0\%$ ), indicating that different intervention parameters have little influence on the results.

### 3.7. Meta-regression analysis

The source of heterogeneity was further explored through meta-regression analysis. Covariates included published year, country where research was conducted, study design (RCT or observational study), interventional parameters (CF, ECI, or AI), mean age and male proportion of participants. The detailed results of the meta-regression analysis are showed in Table 3. All of above included covariates are not the main factors affecting heterogeneity between studies (p > 0.10).

## 4. Discussion

In this study, we compared the efficacy and safety of CTI ablation between CF related parameters guidance and the conventional method. To our knowledge, it is the first metaanalysis on this issue. The main findings include the following: (1) ablation guided by CF related parameters significantly increases catheter tip-tissue contact; (2) it reduces RF duration and the number of RF lesions but does not significantly reduce total procedural time and fluoroscopy time; (3) it improves the success rate of bidirectional isthmus block after first ablation line achieved, but does not reduce the acute conduction recovery and recurrence rate; (4) it has the same safety compared with the conventional method.

Successful RF lesion formation has been shown to be dependent on transmural necrosis of target tissue, which is associated with several factors including temperature at the catheter-tissue interface, power and time of RF application, among them, good catheter-tissue contact is essential for the formation of effective lesion (9, 32, 33). Previous studies have shown that ablation guided by CF related parameters improved catheter-tissue contact in PVI, and reduced the acute gap formation and conduction recovery (34, 35), despite the latest meta-analysis has shown no significant reduction in recurrence rate (36). Although the value of CF related parameters has been confirmed in AF ablation, they cannot be considered to be identical fully in CTI ablation. Specifically, the structure of CTI is complicated, with the highly non-uniform thickness, as well as the presence of a prominent Eustachian ridge or sub-Eustachian pouches, which may alter the ability to create an

Variable	Slope coefficient	Standard error	Z-value	P-value	95% CI		
					Lower limit	Upper limit	
RF duration							
Published year	-0.041778	0.1990302	-0.21	0.868	-2.570697	2.487141	
Research country	0.0478591	0.8627267	0.06	0.965	-10.91412	11.00984	
Study design	-0.4796924	1.918133	-0.25	0.844	-24.85189	23.8925	
Interventional parameter	-0.3700575	1.088199	-0.34	0.791	-14.19694	13.45682	
Mean age	0.352579	0.5520906	0.64	0.638	-6.662397	7.367555	
Male gender	3.60509	9.821638	0.37	0.776	-121.1907	128.4008	
Procedural time							
Published year	-0.2000909	0.1660483	-1.21	0.441	-2.309935	1.909753	
Research country	-0.0383034	0.515673	-0.07	0.953	-6.59055	6.513943	
Study design	-0.2750035	0.6548081	-0.42	0.747	-8.595129	8.045123	
Interventional parameter	-0.9803946	0.8344757	-1.17	0.449	-11.58341	9.622624	
Mean age	0.1243999	0.1646027	0.76	0.588	-1.967075	2.215875	
Fluoroscopy time	1						
Published year	-0.1397646	0.0628184	-2.22	0.269	-0.9379486	0.6584194	
Research country	0.9589619	0.59878	1.6	0.355	-6.64926	8.567184	
Study design	-1.693153	0.9998991	-1.69	0.340	-14.39808	11.01177	
Interventional parameter	-0.4049631	0.1679673	-2.41	0.250	-2.53919	1.729263	
Mean age	-0.8643761	0.6181539	-1.4	0.395	-8.718766	6.990013	
Male gender	-21.91214	14.32837	-1.53	0.369	-203.9713	160.147	
Number of RF lesio	ns		1		1	1	
Published year	0.3492074	0.1253937	2.78	0.219	-1.244071	1.942486	
Research country	0.4072841	0.2026555	2.01	0.294	-2.167699	2.982267	
Study design	1.166482	0.4745546	2.46	0.246	-4.863306	7.19627	
Interventional parameter	-2.486559	1.047482	-2.37	0.254	-15.79608	10.82297	
Touch-up needed			1			1	
Published year	0.0478391	0.0766701	0.62	0.645	-0.9263472	1.022025	
Study design	-0.0552741	0.4386066	-0.13	0.920	-5.628299	5.517751	
Acute conduction r	ecovery		1			1	
Published year	0.0616289	0.6462428	0.1	0.939	-8.149665	8.272922	
Research country	-0.3444556	3.792939	-0.09	0.942	-48.53832	47.84941	
Study design	-0.1481234	1.674416	-0.09	0.944	-21.4236	21.12736	
Interventional parameter	-10.58069	11.3521	-0.93	0.522	-154.8228	133.6614	
Mean age	-4.791256	5.455508	-0.88	0.541	-74.11005	64.52754	
Male gender	-9.694279	11.71157	-0.83	0.560	-158.5038	139.1153	
Recurrence rates			1			1	
Published year	0.7603328	2.394938	0.32	0.804	-29.67024	31.1909	
Research country	-0.3884593	1.125114	-0.35	0.788	-14.68438	13.90746	
Study design	1.527826	4.029201	0.38	0.769	-49.66803	52.72368	
Mean age	0.1156787	1.155708	0.1	0.936	-14.56898	14.80034	
Complications			I	I	I	I	
Published year	-0.9955774	0.8425855	-1.18	0.447	-11.70164	9.710487	
Research country	-0.7651117	0.8790133	-0.87	0.544	-11.93403	10.40381	
Mean age	0.8118284	0.7133147	1.14	0.459	-8.251694	9.87535	

#### TABLE 3 Results of meta-regression analysis for outcome indicators.

Some covariates were not included in the meta-regression analysis of partial observational indicators because sensitivity analyses by eliminating studies one by one had been performed or the number of including studies was insufficient for analysis.

adequate ablation lesion (31). Therefore, more stable contact is needed to achieve uniform and effective transmural lesions.

Previous studies have shown that the use of conventional parameters during CTI ablation in the absence of real-time CF

sensing resulted in nearly half of all lesions being low CF with marked inhomogeneity of CF in different lesion regions (37). Low CF was implicated in more RF applications, longer time to achieve isthmus block, and increased risk of acute reconnection

10.3389/fcvm.2022.1060542

(27, 31). These findings underscored the importance of realtime CF measurements for optimizing ablation of typical AFL. As a comprehensive review of all relevant high-quality studies, this meta-analysis further confirmed that the use of CF related parameters offered CTI ablation more efficiency. Catheter-tissue contact was significantly increased when the CF was visible, thus reducing the time to acute isthmus block. At the same time, ablation guided by CF related parameters did not result in additional complications, or more steam pops. This is consistent with the results of previous studies of PVI and CTI ablation.

In this study, although no statistically significant differences were found between the two groups in terms of total procedural time and fluoroscopy time, there was a trend toward a decrease in all time parameters in the CF related parameters-guided ablation. We consider that it might be related to the small number of included studies and samples, i.e., sampling error leads to insignificant difference. Moreover, the inexperience of operators in CF related parameters-guided ablation could affect the operation efficiency, which might also lead to potential bias. However, based on the current evidence, CF related parameters guidance cannot be considered to shorten procedural time and fluoroscopy time in CTI ablation.

In terms of ablation effectiveness, although ablation guided by CF related parameters reduces the need for touch-up after completion of the first ablation line, acute reconnection and long-term outcomes are not improved. One possible reason for that is related to inappropriate CF. Specifically, although real-time CF is visible during RF application, the optimal CF value for CTI ablation still has not been confirmed, meaning that the contact may still be poor during ablation and cannot achieve transmural necrosis and lesion durability, thus gradual reconnection may occur after completion of the first ablation line. Furthermore, catheter stability and lesion continuity are also key elements influencing effective linear lesion formation (38, 39). That means excessively wide spacing between ablation points may result in incomplete electrical isolation, and catheter movement during RF application may result in insufficient ablation depth to reach transmural lesions.

In addition to maintain good catheter-tissue contact, adequate energy delivery causing thermal coagulation necrosis is also needed to achieve formation of a line of block across the CTI from the tricuspid annulus to the inferior vena cava, given the inhomogeneity of isthmus anatomy (40). Previous studies have shown that higher power can affect more effective isthmus lines by forming larger and deeper lesions, thus improve the longterm success rate of flutter ablation (41). But it is worth noting that higher power output is also potentially associated with a higher risk of complications, including coronary artery injury, pops, and even cardiac perforation (42). Moreover, the use of large-tip catheters has advantage of creating wider and deeper lesions than the conventional catheter (43). Thereby improving the continuity of lesions. The superior clinical efficacy of 8mm tip electrode catheter compared to the conventional 4mm catheter for flutter ablation has been confirmed by several studies (44). However, the optimal power setting has not been established for CF-guided and temperature controlled flutter ablation with large-tip catheters, and that should be investigated in the future to improve the overall efficacy of this procedure.

Recently, high-power short-duration (HPSD) ablation has been proposed as an effective and safe strategy for CTI ablation, allowing for more rapid superficial tissue ablation while avoiding complications associated with deeper lesions (45). Published studies showed the combined use of HPSD and CF technique was associated with a substantial reduction in total RF time compared to using only HPSD or traditional settings (46).

Notably, this meta-analysis involved three different contact parameters (CF, ECI, and AI), so we conducted a subgroup analysis to explore differences of their effects on CTI ablation. The result showed that effects of all three parameters were similar and did not significantly increase the inter-group heterogeneity, except for that on fluoroscopy time. Specifically, the only article involving AI showed a significant reduction in fluoroscopy time in the intervention group, while the other subgroups and the overall result were not statistically significant (29). We re-analyzed the methodology of this study and found that it was the only prospective, non-randomized study, as well as the only one involving Asians. Of note, the intracardiac echocardiography (ICE) was used in this study, which determined potential benefits in terms of reduction of ionizing radiation duration. The combination of CF related parameters and ICE may further improve ablation efficiency and reduce fluoroscopy time (47). More studies are needed in the future to confirmed it, although it does not have the crucial effect on the overall conclusion of this study.

Overall, CF related parameters offer possible incremental benefits in terms of efficiency without sacrificing safety and effectiveness. More studies are needed in the future to determine the exact optimal parameter values and verify its benefits of combination of it and other tools, as noted above.

## 5. Limitations

A limitation of this study is that some studies are of limited quality, given their characteristics such as non-RCTs, open-label design or funding from related instrument companies, that pose potential bias risk. Another limitation is that, moderate-high heterogeneity is found in some of the results, that should be interpreted with caution. It is associated with the quality of included data was not high enough. Although we have analyzed the source of heterogeneity, its effect on outcomes cannot be fully assessed, given differences of basic characteristics of patients and experience of operators. Furthermore, the limited data of included studies lead a lack of discussion about zero X-ray flutter ablation, a strategy with potential clinical benefits in terms of reduction of ionizing radiation exposure (47). With the rapid development of some facilitated tools, including 3D electroanatomic mapping systems, magnetic navigation and ICE, zero X-ray ablation should be more applied to improve safety of procedures and operators. Finally, due to the limited available ablation data, the effect of CF related parameters guidance on different anatomical segments of CTI during AFL ablation cannot be specifically analyzed.

## 6. Conclusion

CF related parameters guidance increases catheter-tissue contact in CTI ablation with the comparable safety as compared with conventional method, thus improves the effect of bidirectional isthmus block after first ablation line finished and reduces RF duration. However, it does not reduce the risks of acute conduction recovery and recurrent atrial arrhythmia.

## Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

## Author contributions

RW and NP: study concept and design. NP and JG: data search and extraction. NP, JG, and NZ: formal analysis and investigation. NP: writing – original draft preparation. NZ and MG: writing – review and editing. All authors contributed to the article and approved the submitted version.

## Funding

This study was supported by the National Natural Science Foundation of China (Grant/Award No. 82000426), the Natural Science Foundation of Shanxi Province, China (Grant/Award Nos. 201801D121222 and 201801D121337), and the Cultivation Project of Young and Middle-aged Academic Leaders of the First Hospital of Shanxi Medical University (Grant/Award No. YD1609).

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fcvm.2022.1060542/full#supplementary-material

**SUPPLEMENTARY FIGURE 1** Forest plots for subgroup analysis of fluoroscopy time.

## References

1. O'Neill M, Jais P, Jönsson A, Takahashi Y, Sacher F, Hocini M, et al. An approach to catheter ablation of cavotricuspid isthmus dependent atrial flutter. *Indian Pacing Electrophysiol J.* (2006) 6:100–10.

2. Saoudi N, Cosío F, Waldo A, Chen S, Iesaka Y, Lesh M, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a statement from a joint expert group from the working group of arrhythmias of the European society of cardiology and the North American society of pacing and electrophysiology. *Eur Heart J.* (2001) 22:1162–82. doi: 10.1053/euhj.2001.2658

3. Cauchemez B, Haissaguerre M, Fischer B, Thomas O, Clementy J, Coumel P. Electrophysiological effects of catheter ablation of inferior vena cava-tricuspid annulus isthmus in common atrial flutter. *Circulation.* (1996) 93:284–94.

4. Pérez F, Schubert C, Parvez B, Pathak V, Ellenbogen K, Wood M. Longterm outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis. Circ Arrhythm Electrophysiol. (2009) 2:393–401. doi: 10. 1161/CIRCEP.109.871665

5. Giehm-Reese M, Kronborg M, Lukac P, Kristiansen S, Nielsen J, Johannessen A, et al. Recurrent atrial flutter ablation and incidence of atrial fibrillation ablation after first-time ablation for typical atrial flutter: a nation-wide danish cohort study. *Int J Cardiol.* (2020) 298:44–51. doi: 10.1016/j.ijcard.2019.07.

 Reynolds M, Calkins H, Sondhi M, Xu Y, Martin A, Williams C, et al. Metaanalysis of ablation of atrial flutter and supraventricular tachycardia. *Am J Cardiol.* (2009) 104:671–7.

7. Holmes D, Fish J, Byrd I, Dando J, Fowler S, Cao H, et al. Contact sensing provides a highly accurate means to titrate radiofrequency ablation lesion depth. *J Cardiovasc Electrophysiol.* (2011) 22:684–90. doi: 10.1111/j.1540-8167.2010.01 963.x

8. Avitall B, Mughal K, Hare J, Helms R, Krum D. The effects of electrode-tissue contact on radiofrequency lesion generation. *Pacing Clin Electrophysiol.* (1997) 20:2899–910.

9. Ikeda A, Nakagawa H, Lambert H, Shah D, Fonck E, Yulzari A, et al. Relationship between catheter contact force and radiofrequency lesion size and incidence of steam pop in the beating canine heart: electrogram amplitude, impedance, and electrode temperature are poor predictors of electrode-tissue contact force and lesion size. *Circ Arrhythm Electrophysiol.* (2014) 7:1174–80. doi: 10.1161/CIRCEP.113.001094

10. Thiagalingam A, D'Avila A, Foley L, Guerrero J, Lambert H, Leo G, et al. Importance of catheter contact force during irrigated radiofrequency ablation: evaluation in a porcine ex vivo model using a force-sensing catheter. *J Cardiovasc Electrophysiol.* (2010) 21:806–11. doi: 10.1111/j.1540-8167.2009.01 693.x

11. Shah D, Lambert H, Nakagawa H, Langenkamp A, Aeby N, Leo G. Area under the real-time contact force curve (force-time integral) predicts radiofrequency lesion size in an *in vitro* contractile model. *J Cardiovasc Electrophysiol.* (2010) 21:1038–43. doi: 10.1111/j.1540-8167.2010.01750.x

12. Kuck K, Reddy V, Schmidt B, Natale A, Neuzil P, Saoudi N, et al. A novel radiofrequency ablation catheter using contact force sensing: toccata study. *Heart Rhythm.* (2012) 9:18–23. doi: 10.1016/j.hrthm.2011.08.021

13. Das M, Loveday J, Wynn G, Gomes S, Saeed Y, Bonnett L, et al. Ablation index, a novel marker of ablation lesion quality: prediction of pulmonary vein reconnection at repeat electrophysiology study and regional differences in target values. *Europace*. (2017) 19:775–83. doi: 10.1093/europace/euw105

14. Qi Z, Luo X, Wu B, Shi H, Jin B, Wen Z. Contact force-guided catheter ablation for the treatment of atrial fibrillation: a meta-analysis of randomized, controlled trials. *Braz J Med Biol Res.* (2016) 49:e5127. doi: 10.1590/1414-431X20155127

15. Ioannou A, Papageorgiou N, Lim W, Wongwarawipat T, Hunter R, Dhillon G, et al. Efficacy and safety of ablation index-guided catheter ablation for atrial fibrillation: an updated meta-analysis. *Europace*. (2020) 22:1659–71. doi: 10.1093/europace/euaa224

16. Shurrab M, Di Biase L, Briceno D, Kaoutskaia A, Haj-Yahia S, Newman D, et al. Impact of contact force technology on atrial fibrillation ablation: a meta-analysis. *J Am Heart Assoc.* (2015) 4:e002476.

17. Moher D, Liberati A, Tetzlaff J, Altman D, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* (2009) 6:e1000097. doi: 10.1371/journal.pmed.100 0097

18. Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med.* (2011) 155:529–36.

19. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res.* (2018) 27:1785–805.

20. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol.* (2014) 14:135. doi: 10.1186/1471-2288-14-135

21. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. *BMJ.* (2003) 327:557-60.

22. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. *Stat Med.* (2002) 21:1539–58.

23. Begg G, O'Neill J, Sohaib A, McLean A, Pepper C, Graham L, et al. Multicentre randomised trial comparing contact force with electrical coupling index in atrial flutter ablation (VERISMART trial). *PLoS One.* (2019) 14:e0212903. doi: 10.1371/journal.pone.0212903

24. Giehm-Reese M, Kronborg M, Lukac P, Kristiansen S, Jensen H, Gerdes C, et al. A randomized trial of contact force in atrial flutter ablation. *Europace*. (2020) 22:947–55.

25. Jones M, Webster D, Wong K, Hayes C, Qureshi N, Rajappan K, et al. The benefit of tissue contact monitoring with an electrical coupling index during ablation of typical atrial flutter–a prospective randomised control trial. *J Interv Card Electrophysiol.* (2014) 41:237–44. doi: 10.1007/s10840-014-9943-6

26. Boles U, Gul E, Fitzpatrick N, Enriquez A, Conroy J, Ghassemian A, et al. Lesion size index in maximum voltage-guided cavotricuspid ablation for atrial flutter. J Innov Card Rhythm Manag. (2017) 8:2732–8. doi: 10.19102/icrm.2017. 080603

27. Gould P, Booth C, Dauber K, Ng K, Claughton A, Kaye G. Characteristics of cavotricuspid isthmus ablation for atrial flutter guided by novel parameters using a contact force catheter. *J Cardiovasc Electrophysiol.* (2016) 27:1429–36. doi: 10.1111/jce.13087

28. Gül E, Boles U, Haseeb S, Hopman W, Chacko S, Simpson C, et al. Gold-tip versus contact-sensing catheter for cavotricuspid isthmus ablation: a comparative study. *Turk Kardiyol Dern Ars.* (2018) 46:464–70. doi: 10.5543/tkda.2018.44025

29. Sakama S, Yagishita A, Sakai T, Morise M, Ayabe K, Amino M, et al. Ablation index-guided cavotricuspid isthmus ablation with contiguous lesions using fluoroscopy integrated 3D mapping in atrial flutter. *J Interv Card Electrophysiol.* (2022) 64:217–22. doi: 10.1007/s10840-022-01182-4

30. Saraf K, Black N, Garratt C, Muhyaldeen S, Morris G. Local impedanceguided ablation and ultra-high density mapping versus conventional or contact force-guided ablation with mapping for treatment of cavotricuspid isthmus dependent atrial flutter. *Indian Pacing Electrophysiol J.* (2022) 22:188–94. doi: 10. 1016/j.ipej.2022.03.004

31. Venier S, Andrade J, Khairy P, Mondésert B, Dyrda K, Rivard L, et al. Contactforce-guided vs. contact-force-blinded catheter ablation of typical atrial flutter: a prospective study. *Europace*. (2017) 19:1043–8. doi: 10.1093/europace/euw137

32. Kalman J, Fitzpatrick A, Olgin J, Chin M, Lee R, Scheinman M, et al. Biophysical characteristics of radiofrequency lesion formation *in vivo*: dynamics of catheter tip-tissue contact evaluated by intracardiac echocardiography. *Am Heart* J. (1997) 133:8–18. doi: 10.1016/s0002-8703(97)70242-4

33. Bosnos M, Guillén-Rodríguez J, He D, Marcus F. Early assessment of biophysical parameters predicts lesion formation during RF energy delivery *in vitro. Pacing Clin Electrophysiol.* (2010) 33:1082–8. doi: 10.1111/j.1540-8159. 2010.02799.x

34. Kautzner J, Neuzil P, Lambert H, Peichl P, Petru J, Cihak R, et al. EFFICAS II: optimization of catheter contact force improves outcome of pulmonary vein isolation for paroxysmal atrial fibrillation. *Europace*. (2015) 17:1229–35. doi: 10. 1093/europace/euv057

35. Natale A, Reddy V, Monir G, Wilber D, Lindsay B, McElderry H, et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. *J Am Coll Cardiol.* (2014) 64:647–56. doi: 10.1016/j.jacc.2014.04.072

36. Virk S, Ariyaratnam J, Bennett R, Kumar S. Updated systematic review and meta-analysis of the impact of contact force sensing on the safety and efficacy of atrial fibrillation ablation: discrepancy between observational studies and randomized control trial data. *Europace*. (2019) 21:239–49. doi: 10.1093/europace/ euy266

37. Kumar S, Morton J, Lee G, Halloran K, Kistler P, Kalman J. High incidence of low catheter-tissue contact force at the cavotricuspid isthmus during catheter ablation of atrial flutter: implications for achieving isthmus block. *J Cardiovasc Electrophysiol.* (2015) 26:826–31. doi: 10.1111/jce.12707

38. Hutchinson M, Garcia F, Mandel J, Elkassabany N, Zado E, Riley M, et al. Efforts to enhance catheter stability improve atrial fibrillation ablation outcome. *Heart Rhythm.* (2013) 10:347–53. doi: 10.1016/j.hrthm.2012.10.044

39. Ariyarathna N, Kumar S, Thomas S, Stevenson W, Michaud G. Role of contact force sensing in catheter ablation of cardiac arrhythmias: evolution or history repeating itself? *JACC Clin Electrophysiol.* (2018) 4:707–23.

40. Hillock R, Melton I, Crozier I. Radiofrequency ablation for common atrial flutter using an 8-mm tip catheter and up to 150 W. *Europace*. (2005) 7:409–12. doi: 10.1016/j.eupc.2005.03.002

41. Chugh S, Chan R, Johnson S, Packer D. Catheter tip orientation affects radiofrequency ablation lesion size in the canine left ventricle. *Pacing Clin Electrophysiol.* (1999) 22:413–20. doi: 10.1111/j.1540-8159.1999.tb00469.x

42. Ouali S, Anselme F, Savouré A, Cribier A. Acute coronary occlusion during radiofrequency catheter ablation of typical atrial flutter. *J Cardiovasc Electrophysiol.* (2002) 13:1047–9.

43. Nakagawa H, Yamanashi W, Pitha J, Arruda M, Wang X, Ohtomo K, et al. Comparison of *in vivo* tissue temperature profile and lesion geometry for radiofrequency ablation with a saline-irrigated electrode versus temperature control in a canine thigh muscle preparation. *Circulation*. (1995) 91:2264–73. doi: 10.1161/01.cir.91.8.2264

44. Scavée C, Jaïs P, Hsu L, Sanders P, Hocini M, Weerasooriya R, et al. Prospective randomised comparison of irrigated-tip and large-tip catheter ablation of cavotricuspid isthmus-dependent atrial flutter. *Eur Heart J.* (2004) 25:963–9. doi: 10.1016/j.ehj.2004.03.017

45. Bourier F, Duchateau J, Vlachos K, Lam A, Martin C, Takigawa M, et al. Highpower short-duration versus standard radiofrequency ablation: insights on lesion metrics. *J Cardiovasc Electrophysiol*. (2018) 29:1570–5. doi: 10.1111/jce.13724

46. Golian M, Ramirez F, Alqarawi W, Hansom S, Nery P, Redpath C, et al. High-power short-duration radiofrequency ablation of typical atrial flutter. *Heart Rhythm O2.* (2020) 1:317–23.

47. Mascia G, Giaccardi M. A new era in zero X-ray ablation. Arrhythm Electrophysiol Rev. (2020) 9:121–7. doi: 10.15420/aer.2020.02